Abstracts Archive - Page 320 of 2425 - ACR Meeting Abstracts

Abstract Number: 1303 • ACR Convergence 2023
Patient’s and Physician’s Evaluation of Global Assessment of Disease Activity over Follow up and Across Disease Activity Levels in Recent-Onset Rheumatoid Arthritis
Audrey-Anne Couture¹, Nathalie Carrier², Hugues Allard-Chamard³, Sophie ROUX³, Patrick Liang³ and Gilles Boire³, ¹University of Montréal, Montréal, QC, Canada, ²CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada, ³Université de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Composite measures (e.g. SDAI) to assess Rheumatoid Arthritis (RA) disease activity incorporate patient (PGA) and evaluator (EGA) global assessments. EGA and PGA are often…
Abstract Number: 1168 • ACR Convergence 2023
Evaluation of Agreement Between Functional and Radiological Changes in Idiopathic Inflammatory Myositis (IIM) Associated Interstitial Lung Disease (ILD)
Sonali Narain¹, Can Hu², Michael Liu¹, Himanshu Vashistha¹, Kourosh Shargani³ and Galina Marder¹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Fort Lee, NJ, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY
Background/Purpose: ILD is a major cause of morbidity and mortality in IIM. The diagnosis and progression of ILD often relies on high resolution computed tomography…
Abstract Number: 1252 • ACR Convergence 2023
Physician Global Assessment of Disease Activity in Childhood-Onset Systemic Lupus Erythematosus – Does the Approach Matter?
Ekemini Ogbu¹, Hermine Brunner², Jennifer Huggins³, Angela Merritt³, Megan Quilan-Waters³, Catherine Robben³, Chen Chen³, Daniel J Lovell⁴ and Bin Huang³, ¹Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Johns Hopkins University, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH
Background/Purpose: Physician Global Assessment of Disease Activity (PhGA) are commonly used outcome measures in pediatric rheumatology. For childhood-onset systemic lupus erythematosus (cSLE), the traditional visual…
Abstract Number: 1296 • ACR Convergence 2023
Decline in Incidence of Extraarticular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study
Bradly Kimbrough¹, Cynthia Crowson¹, John Davis¹, Eric Matteson² and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN
Background/Purpose: Extraarticular manifestations of rheumatoid arthritis (ExRA) are associated with increased disease burden and mortality. They are also common, affecting about half of patients with…
Abstract Number: 1316 • ACR Convergence 2023
Influence of Rheumatoid Factor on Serum Drug Levels of TNF Inhibitors with Different Structures in Rheumatoid Arthritis
Ana Martinez Feito¹, Chamaida Plasencia-Rodríguez², Marta Novella-Navarro², Johanna E. Gehin³, Borja Hernandez-Breijo⁴, Claudia M.Brenis⁵, Alejandro Villalba⁶, Elisa Fernandez-Fernandez⁴, Irene Monjo⁷, Dora Pascual-Salcedo⁸, Pilar Nozal⁹ and Alejandro Balsa², ¹Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Dept. of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁴La Paz University Hospital, Madrid, Spain, ⁵VIB-UGent Inflammation Research Center Gent, Belgium, Gent, Belgium, ⁶Rheumatology Department, La Paz University Hospital, Madrid, Spain, ⁷University Hospital La Paz, Madrid, Spain, ⁸Immuno-Rheumatology Research Group, La Paz University Hospital, Madrid, Spain, ⁹Immunology Unit in La Paz University Hospital-Idipaz, Madrid, Spain
Background/Purpose: Elevated rheumatoid factor (RF) in patients with rheumatoid arthritis (RA) is associated with higher disease activity. A significantly lower efficacy of TNF inhibitors (TNFi)…
Abstract Number: 1311 • ACR Convergence 2023
T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Sumei Tang¹, Gong Cheng¹, Yingni Li¹, Yun Li¹, Feng Sun¹, Xiaolin Sun¹, Jiahui Cheng¹, Ru Li¹ and Zhanguo Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the immune cell profiles of patients who were inadequate responders to Etanercept-Biosimilar Yisaipu (Yisaipu-IRs) and…
Abstract Number: 1306 • ACR Convergence 2023
Statin Use Attenuates the Impact of Systemic Inflammation on Ischemic Cardiovascular Risk in Patients with Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth², Piet Van Riel³, Elena Myasoedova⁴, Miguel A Gonzalez-Gay⁵, Alfonso Corrales⁶, Solbritt Rantapaa-Dahlqvist⁷, Petros Sfikakis⁸, Patrick Dessein⁹, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawi¹¹, Virginia Pascual Ramos¹², Irazú Contreras Yañez¹³, Iris Colunga¹⁴, Dionicio A. Galarza-Delgado¹⁴, José Ramón Azpiri-López¹⁴, Silvia Rolefstad¹⁵, Anne Grete Semb¹⁶, Durga P Misra¹⁷, George Kitas¹⁸ and Ellen-Margrethe Hauge¹⁹, ¹Harbor-UCLA Medical Center, Torrance, CA, ²The Lundquist Institute, Torrance, CA, ³Radboud University Medical Center, Drunen, Netherlands, ⁴Mayo Clinic, Rochester, MN, ⁵IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁶Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁷Umeå University, Umeå, Umea, Sweden, ⁸National Kapodistrian University of Athens Medical School, Athens, Greece, ⁹University of Witwatersrand, Johannesburg, South Africa, ¹⁰University of Manitoba, Manitoba, MB, Canada, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹⁴Hospital Universitario UANL, Monterrey, Mexico, ¹⁵Diakonhjemmet Hospital, Oslo, Norway,, Oslo, Norway, ¹⁶Diakonhjemmet Hospital, Oslo, Norway, ¹⁷Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁸The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ¹⁹Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Baseline and cumulative inflammation have both been associated with increased cardiovascular event (CVE) risk in patients with rheumatoid arthritis (RA). Statin therapy reduced systemic…
Abstract Number: 1180 • ACR Convergence 2023
Machine Learning Approach for the Prediction of anti-MDA5 Positive Dermatomyositis Mortality
Xinlei Liu¹, Fumin Qi², Wei Wei¹ and Yin Zhao¹, ¹Tianjin Medical University General Hospital, Tianjin, China, ²Tianjin Medical University, Tianjin, China
Background/Purpose: We describe a single-center clinical cohort of MDA5 positive dermatomyositis(DM) in China and apply a machine learning approach to predict the risk of mortality…
Abstract Number: 1273 • ACR Convergence 2023
Long-term Follow-up of Treated-to-target RA and UA: Results of the BeSt and IMPROVED Studies
Sascha Heckert¹, Johanna Maria Maassen¹, Isabell Nevins², F. Fodili³, Margreet Steup-Beekman⁴, Thomas Huizinga¹, Sytske Anne Bergstra¹ and CF Allaart¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Amsterdam, Netherlands, ³Stichting ReumaZorg ZWN, Roosendaal, Netherlands, ⁴Leiden University Medical Center, Den Haag, Netherlands
Background/Purpose: In 2 trials with an original follow-up of 5-10 years, patients with early arthritis were treated to target, resulting in low disease activity or…
Abstract Number: 1261 • ACR Convergence 2023
Network Analysis of Depression and Anxiety Symptoms in Chinese Rheumatoid Arthritis Patients
Zhang Lijuan and Wu Beiwen, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Rheumatoid arthritis (RA) patients are susceptible to comorbid anxiety and depression. From the network model perspective, comorbidity is due to direct interactions between depression…
Abstract Number: 1327 • ACR Convergence 2023
Effects of Long-Term Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis on Body Weight and Blood Pressure: A Pooled Analysis of Individual Patient Data from Five Randomised Trials
Andriko Palmowski¹, Sabrina Mai Nielsen², Zhivana Boyadzhieva³, Linda Hartman⁴, Judith Oldenkott⁵, Björn Svensson⁶, Ingiäld Hafström⁷, Siegfried Wassenberg⁸, Ernest Choy⁹, John Kirwan¹⁰, Robin Christensen¹¹, Maarten Boers¹² and Frank Buttgereit¹³, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ³Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Charite - University Medicine Berlin, Berlin, Germany, ⁶Lund University, Lund, Sweden, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸Rheumazentrum Ratingen, Ratingen, Germany, ⁹Section of Rheumatology, Cardiff University, Cardiff, United Kingdom, ¹⁰University of Bristol, Bristol, United Kingdom, ¹¹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹²Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ¹³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: High-dose glucocorticoids (GCs) can cause weight gain and hypertension. It is unclear whether GCs at ≤7.5mg/day prednisone equivalent ("low dose"), administered for rheumatoid arthritis…
Abstract Number: 1319 • ACR Convergence 2023
Real World Data on Antifibrotics in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients
Belén Atienza-Mateo¹, Ana Serrano-Combarro², Maria Martin-Lopez³, Santos Castañeda⁴, Rafael Benito Melero-Gonzalez⁵, Jesus Loarce-Martos⁶, Natalia Mena Vazquez⁷, Carmen carrasco-Cubero⁸, Carolina Diez-Morrondo⁹, David Castro-Corredor¹⁰, Tomás Vazquez-Rodriguez¹¹, andrea Garcia-Valle¹², Gema Bonilla¹³, Marina Rodriguez-lopez¹⁴, Ignacio Brana Abascal¹⁵, SARA MARIA ROJAS HERRERA¹⁶, Juan Camilo Sarmiento-Monroy¹⁷, Pablo Andujar-Brazal¹⁸, Juan Ramon De Dios¹⁹, Carmen Gonzalez-Montagut Gomez²⁰, Sergio Ordonez-Palau²¹, Anahy Maria Brandy-Garcia²², Fernando Lozano²³, Maria Lopez-Lasanta²⁴, Cristina Campos Fernández²⁵, Marta Garijo Bufort²⁶, Ivette Casafont-Sole²⁷, Calderon Goercke²⁸, Carlota Laura Iñiguez²⁹, Francisco Ortiz-Sanjuán³⁰, Emilio Giner-Serret³¹, Bryan Josue Flores Robles³², Mireia Moreno³³, Evelin Cecilia Cervantes-Perez³⁴, Diego Ferrer³⁵, Ricardo Blanco³⁶ and On behalf of the Collaborative Group Members³⁷, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ³Hospital 12 de Octubre, Madrid, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶Ramón y Cajal University Hospital, Madrid, Spain, ⁷IBIMA, Málaga, Spain, ⁸Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ⁹Division of Rheumatology, Hospital de León, León, Spain, ¹⁰General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ¹¹Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, ¹²Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹³Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ¹⁴Division of Rheumatology, Hospital Clínico Universitario de Santiago, La Coruna, Spain, ¹⁵Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Division of Rheumatology, Hospital de Mérida, Mérida, Spain, ¹⁷Hospital Clínic, Barcelona, Spain, ¹⁸Division of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁹Hospital Universitario Araba, Vitoria, Spain, ²⁰H. Clínico Universitario de Valladolid, Valladolid, Spain, ²¹H. Arnau de Vilanova, Lleida, Spain, ²²Hospital Germans Trias i Pujol, Badalona, Spain, ²³Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁴Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²⁵Hospital General Universitario Valencia, Valencia, Spain, ²⁶H. de Sagunto, Valencia, Italy, ²⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²⁹Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁰Hospital Universitario y Politécnico La Fe, Valencia, Spain, ³¹Hospital Royo Villanova, Teruel, Spain, ³²Hospital Universitario San Pedro, Logroño, Spain, ³³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ³⁴Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁵Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁷Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumatoid Arthritis, Spain, Spain
Background/Purpose: Interstitial lung disease (ILD) is a critical complication of rheumatoid arthritis (RA). Abatacept and rituximab are the preferred disease-modifying antirheumatic drugs (DMARDs) for RA-ILD.…
Abstract Number: 1288 • ACR Convergence 2023
Frailty Is Associated with Higher Risk of Readmission in Patients with Rheumatoid Arthritis
Waqas Tahir¹, Yenny Rosli², Christopher Leung³, K Wysham⁴, Jiha Lee⁵, Radjiv Goulabchand⁶, Una Makris⁷, Siddharth Singh⁸ and Namrata Singh⁹, ¹Mayo Clinic, Jacksonville, FL, ²University of Washington, Seattle, WA, ³Georgetown University School of Medicine, Washington, DC, ⁴VA Puget Sound/University of Washington, Seattle, WA, ⁵University of Michigan, Ann Arbor, MI, ⁶University of California San Diego, La Jolla, CA, ⁷UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁸University of California San Diego, San Diego, CA, ⁹University of Washington, Bellevue, WA
Background/Purpose: With the advent of new therapies and increasing life expectancy, there is a rising number of older adults living with rheumatoid arthritis (RA). Patients…
Abstract Number: 1304 • ACR Convergence 2023
Window of Opportunity to Achieve Better Functional Outcomes in Patients with RA: Effectiveness of an Early Treatment Strategy
Vivian Bykerk¹, Isabel Castrejon², Vibeke Strand³, Stephanie Dahan⁴, Raul Castellanos-Moreira⁵, Leo Chen⁶ and Wayne Little⁴, ¹Department of Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital Universitario Gregorio Marañón, Madrid, Spain, ³Stanford University, Palo Alto, CA, ⁴Bristol Myers Squibb, Princeton, NJ, ⁵Bristol Myers Squibb, Madrid, Spain, ⁶Syneos Health, Vancouver, BC, Canada
Background/Purpose: RA is a chronic disease that can lead to irreversible damage and functional decline with delayed or inadequate treatment.1 Abatacept + MTX is effective…
Abstract Number: 1326 • ACR Convergence 2023
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 204 from the SELECT-CHOICE Study
Andrea Rubbert-Roth¹, Koji Kato², Boulos Haraoui³, Maureen Rischmueller⁴, Yanxi Liu², Nasser Khan⁵, Heidi Camp² and Ricardo Xavier⁶, ¹Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ²AbbVie, Inc., North Chicago, IL, ³Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁴The Queen Elizabeth Hospital and Basil Hetzel Institute; Adelaide Medical School, University of Adelaide, Adelaide, Australia, ⁵Pharmacovigilance and Patient Safety, AbbVie, Inc., North Chicago, IL, ⁶Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: To evaluate the long-term safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, through week 204 in patients with RA from the long-term…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].